Quantinno Capital Management LP Boosts Holdings in Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

Quantinno Capital Management LP grew its stake in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA - Free Report) by 706.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,969 shares of the pharmacy operator's stock after purchasing an additional 167,292 shares during the period. Quantinno Capital Management LP's holdings in Walgreens Boots Alliance were worth $1,782,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Walgreens Boots Alliance by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 86,335,084 shares of the pharmacy operator's stock valued at $805,506,000 after acquiring an additional 2,279,495 shares in the last quarter. Invesco Ltd. boosted its position in shares of Walgreens Boots Alliance by 8.8% during the fourth quarter. Invesco Ltd. now owns 32,572,567 shares of the pharmacy operator's stock valued at $303,902,000 after purchasing an additional 2,631,332 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Walgreens Boots Alliance by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 20,779,254 shares of the pharmacy operator's stock valued at $194,082,000 after purchasing an additional 1,020,587 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Walgreens Boots Alliance by 19.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,155,138 shares of the pharmacy operator's stock worth $122,737,000 after purchasing an additional 2,185,950 shares during the period. Finally, Northern Trust Corp raised its holdings in Walgreens Boots Alliance by 18.8% in the fourth quarter. Northern Trust Corp now owns 8,896,742 shares of the pharmacy operator's stock worth $83,007,000 after purchasing an additional 1,407,973 shares in the last quarter. Hedge funds and other institutional investors own 58.59% of the company's stock.

Walgreens Boots Alliance Price Performance

Shares of WBA opened at $11.18 on Thursday. Walgreens Boots Alliance, Inc. has a twelve month low of $8.08 and a twelve month high of $16.74. The company has a market capitalization of $9.67 billion, a P/E ratio of -1.09, a price-to-earnings-growth ratio of 1.31 and a beta of 0.77. The firm has a 50 day moving average of $11.02 and a 200 day moving average of $10.39. The company has a quick ratio of 0.30, a current ratio of 0.64 and a debt-to-equity ratio of 0.68.

Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) last posted its earnings results on Tuesday, April 8th. The pharmacy operator reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.53 by $0.10. The business had revenue of $38.59 billion during the quarter, compared to analyst estimates of $37.90 billion. Walgreens Boots Alliance had a positive return on equity of 17.61% and a negative net margin of 5.87%. The company's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.20 EPS. As a group, equities research analysts anticipate that Walgreens Boots Alliance, Inc. will post 1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Chairman Stefano Pessina bought 832,258 shares of the company's stock in a transaction that occurred on Sunday, April 27th. The shares were bought at an average price of $11.01 per share, for a total transaction of $9,163,160.58. Following the completion of the acquisition, the chairman now owns 145,621,079 shares of the company's stock, valued at $1,603,288,079.79. This trade represents a 0.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 17.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Walgreens Boots Alliance from a "hold" rating to a "sell" rating and dropped their target price for the company from $11.00 to $9.00 in a report on Friday, February 28th. Wolfe Research raised shares of Walgreens Boots Alliance to a "hold" rating in a research note on Monday, February 24th. Truist Financial cut their price objective on shares of Walgreens Boots Alliance from $13.00 to $12.00 and set a "hold" rating on the stock in a report on Friday, January 31st. Finally, StockNews.com initiated coverage on shares of Walgreens Boots Alliance in a report on Wednesday. They set a "hold" rating for the company. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $10.59.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.

Want to see what other hedge funds are holding WBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Walgreens Boots Alliance, Inc. (NASDAQ:WBA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.